Laxmi Dental Ltd Q3 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 3 Aug 2026 | Healthcare Equipment & Supplies | Market Cap: ₹1.1K Cr
International business expected to grow at 20%-25% CAGR over the next 2-3 years, especially with tariff reductions in the US improving competitiveness. FY27 expected to be comparatively better due to improved tariff situation and EU-India Free Trade Agreement (FTA).
From Laxmi Dental Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹198
Market Cap
₹1.1K Cr
P/E Ratio
31.9
How does Laxmi Dental Ltd rank in Healthcare Equipment & Supplies?
Compare Laxmi Dental Ltd against every Healthcare Equipment & Supplies company this quarter on revenue, margins and earnings-call signals.
Laxmi Dental Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹74 Cr, net profit ₹10 Cr.
Full financials →📊 Revenue & Sales Performance
- →International business expected to grow at 20%-25% CAGR over the next 2-3 years, especially with tariff reductions in the US improving competitiveness.
- →Domestic lab business anticipated to rebound with 20%-25% growth if no exceptional market disruptions occur, supported by consolidation and digital dentistry adoption.
- →Scanner sales growth to continue, with digital penetration in India planned to increase from 79% to 90%, driving future expansion.
- →Aligner segment expected to show growth from Q4 FY26 onwards due to new product launches and normalization of pricing pressure.
- →Kids-e-Dental business projected to scale solidly over 2-3 years, aided by CE certification and European market expansion.
- →Overall revenue target includes sustaining 14.3% growth seen in 9MFY26, with healthier prospects post tariff stabilization and digital adoption.
- →Management targets EBITDA margins improving back to 18%-20% in coming years alongside revenue growth.
📈 Profitability & Margins
- →FY27 expected to be comparatively better due to improved tariff situation and EU-India Free Trade Agreement (FTA).
- →Anticipated revenue growth of 20%-25% in both international and domestic markets, assuming no exceptional adverse events.
- →EBITDA margins expected to improve to between 18%-20%, recovering from current ~15% annual run rate.
- →ESOP costs likely to reduce by about half compared to current year, aiding profitability.
- →Scanner sales and digital dentistry adoption continue to drive future growth; digital penetration targeted to increase from 79% to 90%.
- →New product launches, including AI initiatives and pediatric dental business (Kids-e-Dental) with CE certification pending, expected to accelerate growth.
- →Operating environment stabilization in the US and tariff reductions from 50% to 25% anticipated to improve competitiveness and margins.
- →Management confident in sustaining long-term strong growth based on 36 years of experience and leadership position in the dental industry.
🏗️ Capital Expenditure Plans
- →Laxmi Dental Limited is focusing on digital dentistry expansion, aiming to increase digital penetration from 79% to 90% by pushing scanner sales and Scan as a Service models.
- →The company is investing in innovative products, including AI initiatives (AI-Dent), which are in pilot and soft-launch phases, showing promising potential.
- →There is ongoing investment in pediatric dental products (Kids-e-Dental), including efforts to secure CE certification for expansion into Europe.
- →The company is leveraging new technology adoption to consolidate its leadership and expand into new international markets (currently present in 95 countries).
- →No specific large-scale capex figures or strategic capital investment announcements were highlighted, but continuous technological upgrades and product development efforts indicate ongoing capital allocation toward digital infrastructure and innovation.
💰 Fundraising & Capital Structure
- →No mention of any current or future fundraising through debt or equity was made during the earnings call.
- →The company is currently debt-free, having significantly reduced finance costs in Q3 FY26 to INR 0.3 crore from INR 1.5 crore.
- →No plans for raising capital via equity were discussed or indicated by management.
- →The focus remains on organic growth through expanding product offerings, increasing digital penetration, and geographic expansion.
- →Management emphasized strong internal cash flow and commitment to growth without the need for external capital raising at this time.
📋 Order Book & Pipeline
Key Metrics
Continue your research
What Laxmi Dental's management said in earlier quarters
Others in Healthcare Equipment & Supplies this season
- Tarsons Products Ltd (Q3 FY26)
Tarsons has undertaken a significant capex of INR 600 crores announced in 2021-22, with partial commercialization in 2026. Key concall takeaways from Tarsons…
- Poly Medicure (Q3 FY26)
New acquisitions and subsidiaries, such as Plan1 Health (oncology business), are contributing significant growth (e.g., 30-35% year-on-year for Plan1 Health)…
Frequently Asked Questions
What were Laxmi Dental Ltd Q3 FY26 results?
International business expected to grow at 20%-25% CAGR over the next 2-3 years, especially with tariff reductions in the US improving competitiveness. FY27 expected to be comparatively better due to improved tariff situation and EU-India Free Trade Agreement (FTA).
What is Laxmi Dental Ltd share price analysis?
Laxmi Dental Ltd currently shows a neutral. The stock trades at a P/E of 31.9 with a market cap of ₹1,110 Cr. Investors should review the full earnings analysis for detailed insights.
Is Laxmi Dental Ltd planning capital expenditure?
Laxmi Dental Limited is focusing on digital dentistry expansion, aiming to increase digital penetration from 79% to 90% by pushing scanner sales and Scan as a Service models.
Keep Laxmi Dental Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.